Ikena Oncology, Inc. (IKNA) has a consensus analyst rating of Buy, based on 5 analysts covering the stock. Of those, 4 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for IKNA is $1.33, representing a -92.2% downside from the current price of $17.16. Price targets range from a low of $1.33 to a high of $1.33.
